News & Analysis on Clinical Trial Services & Contract Research And Development
Lonza: sale of specialty ingredients business
By Jenni Spinner
- Last updated on
Lonza has inked an agreement to divest its specialty ingredients business to Bain Capital and Cinven, for an enterprise value of $4.7b USD. According to the company, the sale will empower Lonza to refocus its business in service to the healthcare industry.
Lonza chair Albert Baehny said, “Bain Capital and Cinven have shown they understand the value of the experience and expertise of our specialty ingredients employees. They presented the most compelling industrial strategy and vision for the business; they are also keen to prioritize R&D and innovation, as well as to invest in existing facilities to unlock the potential of the business.”